BioCentury | Nov 19, 2020
Product Development

Lucira’s at-home COVID-19 LAMP test breaks barrier, not dam

The first FDA-authorized at-home COVID-19 test makes it possible for symptomatic patients to get a rapid diagnosis while isolating at home, but is unlikely to open the floodgates to routine self-screening....
BioCentury | Aug 18, 2020
Product Development

SalivaDirect slots into growing matrix of resource-saving COVID-19 tests

Yale’s SalivaDirect is the latest FDA-authorized test geared to expand COVID-19 detection by shrinking cost and supply chain issues. The molecular test is most distinguished from other resource-saving...
BioCentury | May 1, 2020
Distillery Therapeutics

LAMP2 gene therapy for cardiomyopathy and liver dysfunction in Danon disease

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiomyopathy Adeno-associated viral vector (AAV)-mediated overexpression of LAMP2 could treat Danon disease, a cardiomyopathy caused by loss-of-function LAMP2 point mutations. Danon disease causes cardiac and skeletal muscle weakness and causes multi-organ...
BioCentury | Feb 29, 2020
Product Development

CRISPR-based diagnostics are poised to make an early debut amid COVID-19 outbreak

CRISPR could see its first direct application to human health much earlier than expected as the COVID-19 outbreak accelerates development timelines for CRISPR-based diagnostics. Diagnostic testing for COVID-19 is currently conducted with real-time PCR tests...
BioCentury | Mar 22, 2019
Clinical News

Biofrontera planning applications to expand Ameluz indication

Biofrontera said it will submit regulatory applications to FDA and EMA in 3Q19 to expand the indication of Ameluz to include treatment of actinic keratoses lesions on the extremities. The decision follows Phase III data...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Cardiovascular

INDICATION: Cardiomyopathy Patient sample studies suggest CRISPR-mediated editing of the B isoform of LAMP2 could help treat Danon disease, a cardiomyopathy caused by a loss-of-function LAMP2 point mutations. In cardiomyocytes from patients, CRISPR-Cas9-mediated correction of...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BioCentury | Apr 10, 2018
Distillery Techniques

Biomarkers

...patients with stage II or III tumors, low ratios of cytotoxic tumor lymphocytes to non-activated CD68 (LAMP4)-expressing...
...doi:10.1158/2326-6066.CIR-17-0360 CONTACT: Yvonne M. Saenger, Columbia University Medical Center, New York, N.Y. email: yms4@cumc.columbia.edu Mark Zipkin Columbia University CD68 (LAMP4) Melanoma Tissue...
BioCentury | Dec 22, 2017
Clinical News

SciFluor reports Phase I/II data for SF0166 in wet AMD

SciFluor Life Sciences Inc. (Cambridge, Mass.) reported top-line data from 42 evaluable patients with wet age-related macular degeneration (AMD) in a Phase I/II trial showing that SF0166 Topical Ophthalmic Solution met the primary safety endpoint...
BioCentury | Oct 6, 2017
Clinical News

SciFluor reports Phase I/II data for DME candidate

SciFluor Life Sciences Inc. (Cambridge, Mass.) reported top-line data from a Phase I/II trial in 40 patients with diabetic macular edema (DME) showing that SF0166 Topical Ophthalmic Solution met the primary safety endpoint with no...
Items per page:
1 - 10 of 81